Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BTC Health Limited (BTC.AX)
Camberwell, VIC, AU
BTC Health Limited operates as a Pooled Development Fund, overseen by LHC Capital Partners Pty Ltd. The fund strategically deploys capital across various corporate development stages, from initial seed and startup funding to early, mid, and late-stage venture growth, and into emerging and established growth companies. Its investment focus lies primarily within the healthcare and biotechnology industries, with a specific emphasis on groundbreaking areas such as post-genomics, which encompasses functional genomics, transcriptomics, proteomics, structural genomics, glycomics, and pharmacogenomics. It also targets stem cell biology, particularly stem cell therapies. Other key areas of interest include convergent technologies, like biomaterials, bionics, biosensors, tissue engineering, microfluidics, and moletronics; silicon biology, involving structure-based drug design, virtual screening, computational library design, and in silico ADME/tox; and nanomedicine. The fund exclusively supports businesses located in Australia, investing in both publicly traded and privately held enterprises.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -14.29% | -10.00% | -12.90% | +3.85% | +170.00% | -22.86% | -58.46% | -89.20% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Biotechnology: +1.6%-39.1% Q4'25: -90.1% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+257.6% ★ Q4'25: -94.3% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-39.9% Q4'25: -30,469.2% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-6,682.0% Q4'25: -10,005.8% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-7.8% ★ Q4'25: -3.6% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+2.5% ★ Q4'25: +6.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×— Q4'25: -0.22× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joshua Kahanovitz | Chief Operations Officer | — | male |
| Salesh Balak | Chief Financial Officer & Company Secretary | — | male |
| Tracy Weimar | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BTC.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
